Bristol-Myers Squibb and Samsung BioLogics have expanded their existing manufacturing agreement in which Samsung will manufacture commercial drug substances and drug product for several BMS biologics at its Incheon manufacturing site in Korea. Financial terms were not disclosed. The companies entered their first manufacturing agreement in July 2013 for the production of a single commercial antibody cancer drug substance.
 
Samsung’s Incheon production facilities provide process development, drug substance manufacturing, and drug product fill and finish services. The company is currently building a second facility in Incheon, which is expected to be completed in early 2015.
 
“Biologic medicines that treat serious diseases are an integral part of Bristol-Myers Squibb’s specialty care portfolio and R&D pipeline,” said Lou Schmukler, president, Global Manufacturing & Supply. “The expanded relationship with Samsung will increase our biologics manufacturing capability and give us the flexibility to respond to increased demand in order to meet the global needs of patients.”
 
“Samsung is delighted to reach the second manufacturing agreement with Bristol-Myers Squibb and we look forward to delivering top quality GMP production,” said Dr. TH Kim, president and chief executive officer of Samsung BioLogics. “It represents another significant step for Samsung and Bristol-Myers Squibb in strengthening our biopharmaceutical manufacturing relationship.”